<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Treatment Response Monitoring** **Açıklama:** 1. **CA-125:** Makalenin birincil biyobelirteci ve ana araştırma konularından biri. 2. **RECIST:** Tedavi yanıtını değerlendirmek &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/treatment-response-monitoring-aciklama-1-ca-125-makalenin-birincil-biyobelirteci-ve-ana-arastirma-konularindan-biri-2-recist-tedavi-yanitini-degerlendirmek/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 20 Jan 2026 18:51:55 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Treatment Response Monitoring** **Açıklama:** 1. **CA-125:** Makalenin birincil biyobelirteci ve ana araştırma konularından biri. 2. **RECIST:** Tedavi yanıtını değerlendirmek &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>CA-125 and RECIST: Key Insights in Ovarian Cancer</title>
		<link>https://bioengineer.org/ca-125-and-recist-key-insights-in-ovarian-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 18:51:32 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CA-125]]></category>
		<category><![CDATA[İşte içerik için 5 uygun etiket: **CA-125]]></category>
		<category><![CDATA[Ovarian cancer prognosis]]></category>
		<category><![CDATA[PARP inhibitors]]></category>
		<category><![CDATA[RECIST]]></category>
		<category><![CDATA[Treatment Response Monitoring** **Açıklama:** 1. **CA-125:** Makalenin birincil biyobelirteci ve ana araştırma konularından biri. 2. **RECIST:** Tedavi yanıtını değerlendirmek]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ca-125-and-recist-key-insights-in-ovarian-cancer/</guid>

					<description><![CDATA[Recent advancements in the treatment of ovarian cancer have increasingly focused on understanding the recurrent patterns of the disease and the prognostic factors associated with its progression. In a groundbreaking study conducted by Zhang et al., the authors delve into the intricate relationship between the biomarker CA-125 and the RECIST criteria, which are essential for [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319096</post-id>	</item>
	</channel>
</rss>
